Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (MYGN) and PATHOMIQ entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States.

LIMA, Peru, Dec. 1, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with the ...

The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, ...

Founded in 2021, T3 Molecular Genetics Pvt Ltd. (T-3MGen) operates in the Health Tech sector offering new therapeutic interventions through multi-disciplinary ...

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed ...

What we choose to study—whether fine art or finance—is one of the most influential decisions in our lives. It shapes not only ...